Archive
API

National Coverage Determination (NCD)

Lung Volume Reduction Surgery (Reduction Pneumoplasty)

240.1

Expand All | Collapse All

Tracking Information

Publication Number
100-3
Manual Section Number
240.1
Manual Section Title
Lung Volume Reduction Surgery (Reduction Pneumoplasty)
Version Number
2
Effective Date of this Version
01/01/2004
Ending Effective Date of this Version
11/17/2005
Implementation Date
01/05/2004
Implementation QR Modifier Date

Description Information

Benefit Category
Inpatient Hospital Services
Outpatient Hospital Services Incident to a Physician's Service
Physicians' Services


Please Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.

Item/Service Description

Lung volume reduction surgery (LVRS) or reduction pneumoplasty, also referred to as lung shaving or lung contouring, is performed on patients with severe emphysema in order to allow the remaining compressed lung to expand, and thus, improve respiratory function.
Indications and Limitations of Coverage

A - Covered Indications

Medicare-covered LVRS approaches are limited to bilateral excision of a damaged lung with stapling performed via median sternotomy or video-assisted thoracoscopic surgery.

  1. National Emphysema Treatment Trial (NETT) participants (effective for services performed on or after August 11, 1997):
    Medicare provides coverage to those beneficiaries who are participating in the NETT trial for all services integral to the study and for which the Medicare statute does not prohibit coverage.
  2. Medicare will only consider LVRS reasonable and necessary when all of the following requirements are met (effective for services performed on or after January 1, 2004):
    1. The patient satisfies all the criteria outlined below:
Assessment Criteria
History and physical examination Consistent with emphysema
BMI, ≤31.1 kg/m 2 (men) or ≤32.3 kg/m 2 (women)
Stable with ≤20 mg prednisone (or equivalent) qd
Radiographic High Resolution Computer Tomography (HRCT) scan evidence of bilateral emphysema
Pulmonary function (pre-rehabilitation) Forced expiratory volume in one second (FEV 1) ≤45% predicted (≥15% predicted if age ≥70 years)
Total lung capacity (TLC) ≥100% predicted post-bronchodilator
Residual volume (RV) ≥150% predicted post-bronchodilator
Arterial blood gas level (pre-rehabilitation) PCO 2, ≤60 mm Hg (PCO 2, ≤55 mm Hg if 1-mile above sea level)
PO2, ≥45 mm Hg on room air (PO2, ≥30 mm Hg if 1-mile above sea level)
Cardiac assessment Approval for surgery by cardiologist if any of the following are present: Unstable angina; left-ventricular ejection fraction (LVEF) cannot be estimated from the echocardiogram; LVEF <45%; dobutamine-radionuclide cardiac scan indicates coronary artery disease or ventricular dysfunction; arrhythmia (>5 premature ventricular contractions per minute; cardiac rhythm other than sinus; premature ventricular contractions on EKG at rest)
Surgical assessment Approval for surgery by pulmonary physician, thoracic surgeon, and anesthesiologist post-rehabilitation
Exercise Post-rehabilitation 6-min walk of ≥140 m; able to complete 3 min unloaded pedaling in exercise tolerance test (pre- and post-rehabilitation)
Consent Signed consents for screening and rehabilitation
Smoking Plasma cotinine level ≤13.7 ng/mL (or arterial carboxyhemoglobin ≤2.5% if using nicotine products)
Nonsmoking for 4 months prior to initial interview and throughout evaluation for surgery
Preoperative diagnostic and therapeutic program adherence Must complete assessment for and program of preoperative services in preparation for surgery
  1. In addition, the patient must have:
    • Severe upper lobe predominant emphysema (as defined by radiologist assessment of upper lobe predominance on CT scan), or
  2. Severe non-upper lobe emphysema with low exercise capacity.
    Patients with low exercise capacity are those whose maximal exercise capacity is at or below 25 watts for women and 40 watts (w) for men after completion of the preoperative therapeutic program in preparation for LVRS.  Exercise capacity is measured by incremental, maximal, symptom-limited exercise with a cycle ergometer utilizing 5 or 10 watt/minute ramp on 30% oxygen after 3 minutes of unloaded pedaling.
  3. The surgery must be performed at facilities that were identified by the National Heart, Lung, and Blood Institute to meet the thresholds for participation in the NETT, and at sites that have been approved by Medicare as lung transplant facilities. These facilities are listed on our Web site at  www.cms.gov/coverage/lvrsfacility.pdf. The CMS is currently working to develop accreditation standards for facilities to perform LVRS and when implemented, will consider LVRS to be reasonable and necessary only at accredited facilities.
  4. The surgery must be preceded and followed by a program of diagnostic and therapeutic services consistent with those provided in the NETT and designed to maximize the patient's potential to successfully undergo and recover from surgery. The program must include a 6- to 10-week series of at least 16, and no more than 20, preoperative sessions, each lasting a minimum of 2 hours.  It must also include at least 6, and no more than 10, postoperative sessions, each lasting a minimum of 2 hours, within 8 to 9 weeks of the LVRS.  This program must be consistent with the care plan developed by the treating physician following performance of a comprehensive evaluation of the patient's medical, psychosocial and nutritional needs, be consistent with the preoperative and postoperative services provided in the NETT, and arranged, monitored, and performed under the coordination of the facility where the surgery takes place.

B - Noncovered Indications

  1. LVRS is not covered in any of the following clinical circumstances:

    1. Patient characteristics carry a high risk for perioperative morbidity and/or mortality;
    2. The disease is unsuitable for LVRS;
    3. Medical conditions or other circumstances make it likely that the patient will be unable to complete the preoperative and postoperative pulmonary diagnostic and therapeutic program required for surgery;
    4. The patient presents with FEVõ ≤20% of predicted value, and either homogeneous distribution of emphysema on CT scan, or carbon monoxide diffusing capacity of ≤20% of predicted value (high-risk group identified October 2001 by the NETT); or
    5. The patient satisfies the criteria outlined above in section 2(a), and has severe, non-upper lobe emphysema with high exercise capacity. High exercise capacity is defined as a maximal workload at the completion of the preoperative diagnostic and therapeutic program that is above 25 w for women and 40 w for men (under the measurement conditions for cycle ergometry specified above).
  2. All other indications for LVRS not otherwise specified remain noncovered.
Cross Reference
Claims Processing Instructions

Transmittal Information

Transmittal Number
3
Coverage Transmittal Link
https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/R3NCD.pdf
Revision History

11/2003 - Expanded coverage to include patients who are: (1) Non high-risk and present with severe, upper-lobe emphysema; or, (2) Non high-risk and present with severe, non upper-lobe emphysema with low exercise capacity. Effective date 1/01/2004. Implementation date 1/5/2004. M+C Implementation date 4/5/2004. (TN 3) (CR 2688)

07/1997 - Provided coverage policy. Effective date 08/11/1997. (TN 102)

12/1995 - Provided noncoverage policy. Effective date NA. (TN 83)
Other

National Coverage Analyses (NCAs)

This NCD has been or is currently being reviewed under the National Coverage Determination process. The following are existing associations with NCAs, from the National Coverage Analyses database.

Coding Analyses for Labs (CALs)

This NCD has been or is currently being reviewed under the National Coverage Determination process. The following are existing associations with CALs, from the Coding Analyses for Labs database.

Additional Information

Other Versions
Title Version Effective Between
Lung Volume Reduction Surgery (Reduction Pneumoplasty) 3 11/17/2005 - N/A View
Lung Volume Reduction Surgery (Reduction Pneumoplasty) 2 01/01/2004 - 11/17/2005 You are here
Lung Volume Reduction Surgery (Reduction Pneumoplasty) 1 08/11/1997 - 01/01/2004 View
CPT Copyright Statement
CPT only copyright 2002-2011 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
Reasons for Denial
Note: This section has not been negotiated by the Negotiated RuleMaking Committee. It includes CMS’s interpretation of it’s longstanding policies and is included for informational purposes. Tests for screening purposes that are performed in the absense of signs, symptoms, complaints, or personal history of disease or injury are not covered except as explicity authorized by statue. These include exams required by insurance companies, business establishments, government agencies, or other third parties. Tests that are not reasonable and necessary for the diagnosis or treatment of an illness or injury are not covered according to the statue. Failure to provide documentation of the medical necessity of tests may result in denial of claims. The documentation may include notes documenting relevant signs, symptoms, or abnormal findings that substantiate the medical necessity for ordering the tests. In addition, failure to provide independent verification that the test was ordered by the treating physician (or qualified nonphysician practitioner) through documentation in the physician’s office may result in denial. A claim for a test for which there is a national coverage or local medical review policy will be denied as not reasonable and necessary if it is submitted without an ICD-9-CM code or narrative diagnosis listed as covered in the policy unless other medical documentation justifying the necessity is submitted with the claim. If a national or local policy identifies a frequency expectation, a claim for a test that exceeds that expectation may be denied as not reasonable and necessary, unless it is submitted with documentation justifying increased frequency. Tests that are not ordered by a treating physician or other qualified treating nonphysician practitioner acting within the scope of their license and in compliance with Medicare requirements will be denied as not reasonable and necessary. Failure of the laboratory performing the test to have the appropriate Clinical Laboratory Improvement Act of 1988 (CLIA) certificate for the testing performed will result in denial of claims.
Submit Feedback/Ask a Question